Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 46

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 46
---
 believed it was appropriate and in the best interests of the Company to have Mr. Simpson's and Mr. Mills' cash incentive awards be based solely upon the achievement of corporate objectives, and the independent Board members concurred. The Compensation Committee believes that including the achievement of individual goals as a component of our cash incentive award payouts is important to motivate our NEOs other than our CEO, as we continue to progress toward the commercial phase of our Company. For 2024, weightings allocated to corporate and individual objectives were as follows:

| Name                 |     | Corporate  
 Objectives 
 Weighting  |     | Individual 
 Objectives 
 Weighting  |
| Curran Simpson       |     | 100%       |     | —          |
| Mitchell Chan        |     | 75%        |     | 25%        |
| Stephen Pakola, M.D. |     | 75%        |     | 25%        |
| Olivier Danos, Ph.D. |     | 75%        |     | 25%        |
| Patrick J. Christmas |     | 75%        |     | 25%        |
| Kenneth T. Mills     |     | 100%       |     | —          |
| Vit Vasista          |     | 75%        |     | 25%        |

The Company’s annual cash incentive program, which is approved by the Compensation Committee and applicable to all employees, utilizes both a corporate performance multiplier and an individual performance multiplier. The corporate performance multiplier is based on the degree to which the Company’s objectives have been achieved during the relevant year; this multiplier is determined by the Compensation Committee and may range from 0 to 200% of target, provided that, if it is determined to be less than 50% of target, there will be no payout for the portion of our annual incentive program that is attributable to corporate performance. The individual performance modifier is based on the degree to which each employee’s individual objectives have been achieved during the relevant year; this multiplier is approved by the Compensation Committee for each of our NEOs and may range from 0 to 200% of target. Corporate Objectives Near the beginning of each year, our management recommends annual corporate objectives to our Compensation Committee and Board for approval. These objectives serve as the basis for determining our performance against key strategic and operating parameters for the year. The Compensation Committee and the Board approved the corporate objectives and weightings for 2024 as reflected in the table below. At the time of